Stocks · Health care · Biological Products, (No Diagnostic Substances)

Metagenomi Therapeutics, Inc.

MGX Clue Score24
United States Fiscal year ends December CIK 0001785279 Results filed 10 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Pamela Wapnick
8 Sep 2026
Chief Financial Officer
Sell
1,911
$1.16
$2.21K
Jian Irish
8 Sep 2026
See Remarks
Sell
2,140
$1.16
$2.48K
Matthew Wein
8 Sep 2026
See Remarks
Sell
358
$1.16
$414.71
Matthew Wein
5 Jun 2026
See Remarks
Sell
558
$1.30
$724.84
Jian Irish
5 Jun 2026
See Remarks
Sell
3,737
$1.30
$4.85K
Pamela Wapnick
5 Jun 2026
Chief Financial Officer
Sell
2,884
$1.30
$3.75K
Jian Irish
5 Mar 2026
Chief Executive Officer
Sell
1,607
$1.60
$2.57K
Matthew Wein
5 Mar 2026
See Remarks
Sell
482
$1.60
$771.20
Pamela Wapnick
5 Mar 2026
Chief Financial Officer
Sell
1,581
$1.60
$2.53K
Jian Irish
5 Dec 2025
Chief Executive Officer
Sell
1,602
$1.77
$2.84K
Pamela Wapnick
5 Dec 2025
Chief Financial Officer
Sell
1,576
$1.77
$2.79K
Matthew Wein
5 Dec 2025
See Remarks
Sell
199
$1.77
$352.61
Brian C. Thomas
5 Dec 2025
Director
Sell
3,830
$1.77
$6.79K
Matthew Wein
5 Sep 2025
See Remarks
Sell
199
$1.81
$360.19
Jian Irish
5 Sep 2025
Chief Executive Officer
Sell
1,602
$1.81
$2.90K
Pamela Wapnick
5 Sep 2025
Chief Financial Officer
Sell
1,576
$1.81
$2.85K
Brian C. Thomas
5 Sep 2025
Director
Sell
2,701
$1.81
$4.89K
Jian Irish
6 Jun 2025
See Remarks
Sell
6,390
$1.75
$11.18K
Brian C. Thomas
6 Jun 2025
Chief Executive Officer
Sell
10,785
$1.75
$18.87K
Pamela Wapnick
6 Jun 2025
Chief Financial Officer
Sell
1,576
$1.75
$2.76K
Sarah B. Noonberg
6 Jun 2025
Chief Medical Officer
Sell
5,239
$1.75
$9.17K
Matthew Wein
6 Jun 2025
See Remarks
Sell
199
$1.75
$348.25
Pamela Wapnick
5 Mar 2025
Chief Financial Officer
Sell
1,808
$1.87
$3.39K
Matthew Wein
5 Mar 2025
See Remarks
Sell
930
$1.87
$1.74K
Pamela Wapnick
5 Dec 2024
Chief Financial Officer
Sell
1,559
$1.86
$2.90K
Pamela Wapnick
5 Sep 2024
Chief Financial Officer
Sell
6,265
$2.88
$18.04K

What was left out

Form 4 filings counted 58
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 26
Transactions with no price 0
Shares from compensation/vesting 8,578,746
History held since 14 Feb 2024